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J.R. Simplot is a privately held $6 billion company, with 0,000 employees. We mine 
phosphate and manufacture fertilizers that we sell to farmers. We’ve been a longstanding 
potato producer in the United States, and we’re involved in livestock. Plant-biotechnology 
work was initiated in 00 with a few scientists. Our mission is to create safe, healthy, 
sustainable crop improvements with a focus on potato. We now number about 65 and 
are in the comment period for our first regulatory submission. We will petition for our 
second-generation biotech crop in six to eight months; our objective is to bring multiple 
products to market.
Building on Biotech
Building a biotech business involves a lot more than science. Certainly, commitment to 
good science is essential. Obtaining proprietary technology is often a necessary part of 
R&D. The regulatory side requires submission of sufficient, but not excessive, data. And 
business development includes determination of the value of the trait in question, and 
building marketplace acceptance. Potato production involves four sub-industries. Each is 
large and comprises varied players, therefore good marketing is essential to build general 
acceptance. The last component is commercialization. It is one thing to obtain regulatory 
approval, but it takes much effort and many trials to bring farmers along; much more is 
involved than running regulatory trials for the USDA.
This area of endeavor is not without controversy and your company culture must 
 inculcate willingness to address such controversy with awareness that you won’t be 
everyone’s best friend all the time.
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Innate Technology
Our marketing effort involves talking about our Innate™ technology:
An innovative biotechnology approach to improving crops using a process that uses 
plant genes to enhance desirable traits and reduce less desirable ones.
Innate™ is a way of putting a plant’s own genes back into a plant. We needed a way to 
introduce our biotech approach to the potato industry and eventually to consumers. As 
part of our market research, we tested several messages and created Innate™ Brand as a 
face for new plant-biotechnology processes for improvements in crops and foods. Innate™ 
provided a way to talk about our technology without resorting to the less consumer-
friendly terms, intragenic and cisgenic.
We take DNA that elicits either expression of (a) desirable trait(s) or less expression 
of (a) less-desirable trait(s) from a cultivated variety or from a wild-species progenitor 
potato, and put it back into Russet Burbank to produce an Innate™ Burbank (Figure ). 
This is the level at which we want to communicate the technology, both to growers and 
to consumers.
Market Research
We’ve done a lot of market research that shows that results depend on how questions are 
worded. However, with enough studies, trends emerge. The data in Figure  demonstrate 
potential consumer acceptance of the Innate™ technology—having explained that it is a 
Figure . Innate™ technology: How it works.
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Figure . Survey: How likely would you be to purchase fruits and
vegetables that are improved using Innate™ technology?
1Pages 87–94.
plant-based gene transfer—in comparison with genetically modified, traditionally bred, 
and “biotechnology” counterparts. It is noteworthy that use of the word “biotechnol-
ogy” elicits greater comfort among consumers than “GMO.” Explanation of the Innate 
technology produced acceptance close to that of plant breeding, but not quite there. Our 
goal is not to be acceptable to everybody, but to be as acceptable as plant breeding, and, 
clearly, we are close, which is a promising message for all using molecular genetics for crop 
improvement, i.e. consumer acceptance of the technology is potentially good.
First Generation of Traits
Traits we are bringing to market using “Innate .0” potato are:
• Reduced black-spot bruise, and
• Reduced asparagine.
Reduced black-spot bruise is a trait similar to non-browning in the Arctic apple.1 We 
had to silence only one of the five or six polyphenol oxidase (PPO) genes, PPO 5 in 
a tuber-specific manner. And we have down-regulated asparagine in tubers—again 
 tuber-specific—by silencing asparagine synthase. Instead of asparagine—a precursor of 
acrylamide—the modified tuber accumulates glutamine, so the nitrogen content stays 
relatively similar and yield is unaltered, which was an unexpected benefit. If asparagine 
synthase is silenced throughout the plant constitutively, growth is compromised.
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Four varieties have been improved via Innate .0: Russet Burbank, Ranger Russet, 
Atlantic and Snowden. Russet Burbank and Russet Ranger are the primary French-fry 
varieties, and Atlantics and Snow are the primary varieties used to make chips. The 
improvements result in benefits to growers, processors and consumers. Browning occurs 
not only after cutting (Figure 3), but also when stacked in storage, which causes pressure 
bruising. Usually, tissue change is minimal, but it does occur and is a significant problem 
in the fresh market. In the French fry and chip industries, brown potatoes are removed and 
used for cattle feed; the grower is penalized and the processing plant loses productivity.
Acrylamide occurs naturally and is present in almost all baked and fried foods. It 
forms at around 300°F. California has a labeling requirement for baked or fried potato 
products containing acrylamide above 300 ppb. In response, some companies mitigate 
the problem via enzyme use, whereas other companies have withdrawn their products 
from the market in California. Figure 4 shows that potato chips made with Atlantics 
accumulated acrylamide at 450 ppb, whereas Innate™ Atlantics contained acrylamide at 
30 ppb. Similar patterns were found with French fries made with Russet Burbank and 
Ranger Russet and their Innate™ counterparts (Figure 4).
Two ingredients contribute to acrylamide formation: asparagine and sugars. We control 
only the asparagine component in the first generation of Innate™ potatoes, and, in general, 
we see reductions in acrylamide content of 50% to 70%.
A key ancillary question: Could the benefit of lowering acrylamide overcome opposition 
of biotech?
Uniformity
Those whose job is to improve potatoes, and who are focusing on the farmer, are missing 
80% of the potential. Downstream companies that make products from potatoes are the 
big sellers. Farmers produce $3.5 billion worth of potatoes every year, whereas somewhere 
around $40 billion worth of French fries are sold. The market is controlled by customers 
who demand uniform quality in their French fries and chips. Figure 5 shows a spidergram 
containing a 5-point hedonic scale. Innate™ potato products must give data identical to 
their non-Innate counterparts in terms of performance from a sensory perspective, aroma, 
crispness, toughness, etc. Although we’ve affected the asparagine content and the PPO, 
we have not affected starch pathways or other metabolism that affect sensory perception, 
which is a major consideration for our customers.
Figure 6 shows field data for Innate™ Russet Burbank in comparison with its parental 
counterpart; these trials are expensive to run. Each comprises an acre or two, and yield-
tracking data are generated using modeling software. We’ve done this a number of times 
and find consistently that there is no difference between Burbank and Innate™ Burbank 
(E), and that’s important because some farmers have been led to believe that yield 
“drag” results from biotech traits.
Second and Future Generations
In 03, we are running over 30 field trials across the United States and Canada, including 
a commercial development trial in Texas. We encourage growers to visit our commercial 
0
Figure 4. Simplot research, 0.
Figure 3. Comparison of an Innate™ potato (left) and a traditional
potato 0 hours after being cut.
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trials. Also, we have advanced regulatory trials for the next generation of Innate™ potatoes. 
Figure 7 shows the traits that we are working on.
Generation .0 will comprise low asparagine and low bruising as mentioned, and less 
sugar when harvested. Our projection is to launch Generation .0 in 05. We expect to 
launch Generation .0 in 07 and, to that end, we are working on a gene that provides 
sugar control. Potatoes are stored at between 48°F and 5°F, sometimes at 46°F. That 
temperature is one of the single most important economic drivers in the potato industry. 
The gene that we’re working on for sugar control allows storage at 38°F, at which several 
post-harvest issues are circumvented because of less disease. We have licensed a gene from 
Jonathan Jones’ lab—the vnt gene—for broad resistance to strains of Phytophthora infes-
tans, which causes late blight. In our research pipeline we are also working on resistance 
to potato virus Y (PVY), on improvements in use efficiencies of water and nitrogen, on 
enhanced vitamin content and on improved tuber set.
Figure 8 demonstrates positive effects of the Innate™ .0 technology on fresh-potato 
quality. As a result of storage at 38°F, zebra-chip discoloration (top left), caused by 
Liberibacter spp. is decreased. And dark “sugar ends” (bottom left)—caused by a high con-
centration of reducing sugars—are alleviated by silencing the gene encoding invertase. 
Figure 5. Spidergram: Ranger Russet and Innate F0 Ranger Russet comparisons
with Russet Burbank gold standard—no sensory differences.
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Figure 6. Russet Burbank and Innate™ E yield comparisons
Figure 7. Future Innate™ traits.
Atlantic is an 85-day potato, whereas most others have a growing season of 0 to40 
days. For this reason, Atlantics are grown all over the world, even though they don’t store 
well; they build sugars too quickly, which causes browning that no one wants. Resistance 
to browning after six months at 38°F means a lot to farmers (Figure 9). The 5,000 thou-
sand acres of Atlantics that are grown in the United States must be shipped to processing 
plants a day or two after they are dug. The Innate™ technology will expand the acreage 
of this variety relative to a number of others.
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Regulatory and Business Considerations
If you create a new potato through biotechnology, using only potato genes, how are you 
regulated? If you used agrobacterium, you’re regulated by the USDA. If you have a novel 
trait, you’ll be regulated by Canada, and if you use recombinant DNA, you’ll be regulated 
Figure 9. Innate Atlantic .0 lines Y9 and Y5 fry with reasonably
good color after six months of storage at 38°F.
Figure 8. Innate™ .0: Impact on fresh-potato quality.
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Figure 0. Innate™ timeline.
(*There is no guarantee that the USDA will
deregulate Innate™ potato products.)
by Japan. Whether the technology is cisgenic or intergenic, it will be treated the same as 
GM in Europe. New TALEN™2 technology has exciting potential, but it is possible that 
deregulation will be needed to protect export markets. We believe that, over the coming 
5 years technology improvement will move back in the direction of transgenics, having 
used within-species manipulations to gain consumer acceptance of genetic approaches. 
Although we are committed to our Innate™ technology, we keep an open mind and avoid 
disparagement of other technologies.
Figure 0 represents our projected regulatory timeline. At this point, June 03, we 
are in a public-comment period from which we expect deregulation of Innate Russet 
Burbank .0, Innate Russet Ranger .0 and Innate Atlantic .0 in 04, and that these 
three products will be on the market in 05. If we are lucky, Innate™ potatoes from the 
04 growing season will be included as ingredients in products available to consumers 
in 05. In 06, we expect deregulation of Innate™ .0 products, with commercial 
introductions of Innate Russet Burbank .0 and Innate Ranger Russet .0 in 06 and 
07, respectively. Deregulation of Innate™ 3.0 technology will be applied for in 08.
2Transcription activator-like effector nuclease.
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Identity Preservation
From the point of view of identity preservation, potatoes have important inherent 
 advantages:
• Potatoes are largely self-pollinating. The flowers have no nectar, and are not visit-
ed by insects. Separation by 0 m is sufficient to eliminate the risk of outcrossing.
• Potatoes are clonally propagated from tubers, not grown from seed.
• Lines can be easily distinguished with PCR.
Business Challenges
The potato market comprises several segments:
• Chips,
• Frozen products (French fries and hashbrowns),
• Fresh potatoes, and
• Dehydrated potatoes.
Each of these entities is supplied to the consumer as different varieties by separate industry 
players. Satisfying the needs of producers presents a challenge to the potato supplier. Regu-
latory approvals vis-à-vis international markets represent another challenge. The capital 
that needs to go into seed potatoes is another issue. The value of US potatoes at the farm 
gate is $3.5 billion, which represents an initial investment of $350 million. Seed-potato 
cost runs at $400 dollars per acre if not more, which is expensive. 
Another issue is the variety of varieties. With eight varieties, we believe that we can 
capture 60% of the potato market. To get to 90% would require double that, and, since 
backcrossing is impossible, each event has to be deregulated. Of course, it will be impos-
sible to capture the whole potato market. Our goal is to capture the majority of the chips 
and the frozen and fresh markets; we expect to leave specialty potatoes to competitors.
Another challenge is the traditional business model for biotech (Figure ). Critical 
aspects are how much the trait improves the crop and market penetration, i.e. how many 
acres; those two are multiplied together to calculate the revenue. If the crop is improved 
by $00 dollars an acre, the grower nets $66 and we get $33. The problem with specialty 
crops is that few traits are available that will pay back the investment. In potato, there 
aren’t many $300 or $400 traits, and a $00 trait won’t pay the bills.
Traditionally, with row crops, new varieties were produced by plant breeders—mainly 
at the universities—which seed companies multiplied and sold (Figure ). Farmers 
planted them, and the produce became widely available. In the biotech industry as soon 
as a stable transformation is achieved, breeding is initiated to put the trait into appropriate 
germplasm; accordingly, genetic manipulation, breeding and seed dissemination are now 
united in one entity, usually achieved through acquisitions. Like the traditional way, the 
biotech product then goes to the farmer, and then it goes worldwide.
With potatoes—and probably a few other crops—the farmer, the food processor and 
the food processor’s customers are vertically integrated (Figure 3). Accordingly, 95% 
of the potatoes that are planted for the French fry industry are contracted by the food 
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Figure . Revenue model for the biotech industry.
Figure . Crop development.
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processor. The food processor tells the farmer which variety to buy, and, if the quick-
service restaurant (QSR) chain is large enough, it tells the food processor which variety 
to make French fries with.
These three entities operate in unison, so if a new variety is to be introduced, all three 
have to be lined up, or markets must be found where at least the food processor and the 
farmer can line up. Fresh and frozen present those opportunities. And food service is 
another. Customers sometimes aren’t picky, so achieving that alignment may be harder 
that it sounds. 
Final Thoughts
We have found the number of traits that are gene-silencing based, which should mean 
a less complicated regulatory package. In terms of reducing expense, not introducing a 
new protein is a significant advantage.
Another thing we have found is that the traits aren’t always obvious. It took us a couple 
of years to fully understand the benefits of the low-sugar trait and its economic implica-
tions. It was necessary to store potatoes for 6 months and then make fries or chips.
A tricky point: the black-spot bruise trait benefits growers, and that benefits processors, 
which benefits the consumer. It’s win-win-win. But it presents a challenge in terms of who 
pays. Presumably it’s the farmer, who must get some of that money from the processor, 
who then must restructure the contracts with reluctant farmers. Calculating value thus 
becomes problematic.
Figure 3. Potato commercialization.
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Lastly, it can take a while to structure relationships and get people comfortable with 
biotech. On the other hand, after they’re comfortable, we’ve seen significant support. We’re 
in a comment period now, and 80 comments have been received, of which probably 5 
are positive, a lot of them from growers. We are excited about that.
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